Quetiapine XR monotherapy in major depressive disorder: A pooled analysis to assess the influence of baseline severity on efficacy

Michael E. Thase, Stuart Montgomery, George I. Papakostas, Michael Bauer, Madhukar H. Trivedi, Henrik Svedsäter, Julie C. Locklear, Urban Gustafsson, Catherine Datto, Hans Eriksson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The efficacy of quetiapine XR was investigated in patients with major depressive disorder and differing levels of baseline severity. Pooled data from four placebo-controlled monotherapy studies of quetiapine XR (50-300 mg/day) were analyzed. Post-hoc analyses were carried out to assess change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) total score at endpoint (week 6 or 8) to week 1, and response (≥50% reduction in MADRS total score) and remission (MADRS total score≤10) rates at endpoint for all patients and six baseline severity cohorts (MADRS total score ≥24, ≥26, ≥28, ≥30, ≥32, and ≥34). In total, 1752 patients (all patients) were evaluated (MADRS score at baseline: ≥24, n=1601; ≥26, n=1467; ≥28, n=1269; ≥30, n=1038; ≥32, n=745; and ≥34, n=500). At endpoint, quetiapine XR reduced MADRS total score in all patients (P<0.001) and each severity cohort (≥24, ≥26, ≥28, ≥30, and ≥32, P<0.001; ≥34, P<0.01) versus placebo. Quetiapine XR also improved MADRS total score at week 1, response rates for each severity cohort, and remission rates in five out of six severity cohorts, versus placebo. Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity.

Original languageEnglish (US)
Pages (from-to)113-120
Number of pages8
JournalInternational Clinical Psychopharmacology
Volume28
Issue number3
DOIs
StatePublished - May 2013

Fingerprint

Major Depressive Disorder
Placebos
Antidepressive Agents
Quetiapine Fumarate
Depression

Keywords

  • atypical antipsychotic
  • extended-release quetiapine fumarate
  • major depressive disorder
  • monotherapy
  • severe depression
  • severity

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Quetiapine XR monotherapy in major depressive disorder : A pooled analysis to assess the influence of baseline severity on efficacy. / Thase, Michael E.; Montgomery, Stuart; Papakostas, George I.; Bauer, Michael; Trivedi, Madhukar H.; Svedsäter, Henrik; Locklear, Julie C.; Gustafsson, Urban; Datto, Catherine; Eriksson, Hans.

In: International Clinical Psychopharmacology, Vol. 28, No. 3, 05.2013, p. 113-120.

Research output: Contribution to journalArticle

Thase, ME, Montgomery, S, Papakostas, GI, Bauer, M, Trivedi, MH, Svedsäter, H, Locklear, JC, Gustafsson, U, Datto, C & Eriksson, H 2013, 'Quetiapine XR monotherapy in major depressive disorder: A pooled analysis to assess the influence of baseline severity on efficacy', International Clinical Psychopharmacology, vol. 28, no. 3, pp. 113-120. https://doi.org/10.1097/YIC.0b013e32835fb971
Thase, Michael E. ; Montgomery, Stuart ; Papakostas, George I. ; Bauer, Michael ; Trivedi, Madhukar H. ; Svedsäter, Henrik ; Locklear, Julie C. ; Gustafsson, Urban ; Datto, Catherine ; Eriksson, Hans. / Quetiapine XR monotherapy in major depressive disorder : A pooled analysis to assess the influence of baseline severity on efficacy. In: International Clinical Psychopharmacology. 2013 ; Vol. 28, No. 3. pp. 113-120.
@article{5046d88df8d74c8c9e89172c7b18c19b,
title = "Quetiapine XR monotherapy in major depressive disorder: A pooled analysis to assess the influence of baseline severity on efficacy",
abstract = "The efficacy of quetiapine XR was investigated in patients with major depressive disorder and differing levels of baseline severity. Pooled data from four placebo-controlled monotherapy studies of quetiapine XR (50-300 mg/day) were analyzed. Post-hoc analyses were carried out to assess change from baseline in the Montgomery {\AA}sberg Depression Rating Scale (MADRS) total score at endpoint (week 6 or 8) to week 1, and response (≥50{\%} reduction in MADRS total score) and remission (MADRS total score≤10) rates at endpoint for all patients and six baseline severity cohorts (MADRS total score ≥24, ≥26, ≥28, ≥30, ≥32, and ≥34). In total, 1752 patients (all patients) were evaluated (MADRS score at baseline: ≥24, n=1601; ≥26, n=1467; ≥28, n=1269; ≥30, n=1038; ≥32, n=745; and ≥34, n=500). At endpoint, quetiapine XR reduced MADRS total score in all patients (P<0.001) and each severity cohort (≥24, ≥26, ≥28, ≥30, and ≥32, P<0.001; ≥34, P<0.01) versus placebo. Quetiapine XR also improved MADRS total score at week 1, response rates for each severity cohort, and remission rates in five out of six severity cohorts, versus placebo. Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity.",
keywords = "atypical antipsychotic, extended-release quetiapine fumarate, major depressive disorder, monotherapy, severe depression, severity",
author = "Thase, {Michael E.} and Stuart Montgomery and Papakostas, {George I.} and Michael Bauer and Trivedi, {Madhukar H.} and Henrik Sveds{\"a}ter and Locklear, {Julie C.} and Urban Gustafsson and Catherine Datto and Hans Eriksson",
year = "2013",
month = "5",
doi = "10.1097/YIC.0b013e32835fb971",
language = "English (US)",
volume = "28",
pages = "113--120",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Quetiapine XR monotherapy in major depressive disorder

T2 - A pooled analysis to assess the influence of baseline severity on efficacy

AU - Thase, Michael E.

AU - Montgomery, Stuart

AU - Papakostas, George I.

AU - Bauer, Michael

AU - Trivedi, Madhukar H.

AU - Svedsäter, Henrik

AU - Locklear, Julie C.

AU - Gustafsson, Urban

AU - Datto, Catherine

AU - Eriksson, Hans

PY - 2013/5

Y1 - 2013/5

N2 - The efficacy of quetiapine XR was investigated in patients with major depressive disorder and differing levels of baseline severity. Pooled data from four placebo-controlled monotherapy studies of quetiapine XR (50-300 mg/day) were analyzed. Post-hoc analyses were carried out to assess change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) total score at endpoint (week 6 or 8) to week 1, and response (≥50% reduction in MADRS total score) and remission (MADRS total score≤10) rates at endpoint for all patients and six baseline severity cohorts (MADRS total score ≥24, ≥26, ≥28, ≥30, ≥32, and ≥34). In total, 1752 patients (all patients) were evaluated (MADRS score at baseline: ≥24, n=1601; ≥26, n=1467; ≥28, n=1269; ≥30, n=1038; ≥32, n=745; and ≥34, n=500). At endpoint, quetiapine XR reduced MADRS total score in all patients (P<0.001) and each severity cohort (≥24, ≥26, ≥28, ≥30, and ≥32, P<0.001; ≥34, P<0.01) versus placebo. Quetiapine XR also improved MADRS total score at week 1, response rates for each severity cohort, and remission rates in five out of six severity cohorts, versus placebo. Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity.

AB - The efficacy of quetiapine XR was investigated in patients with major depressive disorder and differing levels of baseline severity. Pooled data from four placebo-controlled monotherapy studies of quetiapine XR (50-300 mg/day) were analyzed. Post-hoc analyses were carried out to assess change from baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) total score at endpoint (week 6 or 8) to week 1, and response (≥50% reduction in MADRS total score) and remission (MADRS total score≤10) rates at endpoint for all patients and six baseline severity cohorts (MADRS total score ≥24, ≥26, ≥28, ≥30, ≥32, and ≥34). In total, 1752 patients (all patients) were evaluated (MADRS score at baseline: ≥24, n=1601; ≥26, n=1467; ≥28, n=1269; ≥30, n=1038; ≥32, n=745; and ≥34, n=500). At endpoint, quetiapine XR reduced MADRS total score in all patients (P<0.001) and each severity cohort (≥24, ≥26, ≥28, ≥30, and ≥32, P<0.001; ≥34, P<0.01) versus placebo. Quetiapine XR also improved MADRS total score at week 1, response rates for each severity cohort, and remission rates in five out of six severity cohorts, versus placebo. Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity.

KW - atypical antipsychotic

KW - extended-release quetiapine fumarate

KW - major depressive disorder

KW - monotherapy

KW - severe depression

KW - severity

UR - http://www.scopus.com/inward/record.url?scp=84875808005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875808005&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e32835fb971

DO - 10.1097/YIC.0b013e32835fb971

M3 - Article

C2 - 23485955

AN - SCOPUS:84875808005

VL - 28

SP - 113

EP - 120

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 3

ER -